Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
- Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
- Daiichi Sankyo Espha Considers Manufacturing Generics to Be Listed in 2014 at Ranbaxy’s Factory
October 10, 2012
- Chugai Files Avastin for Ovarian Cancer
October 10, 2012
- Ethical Drug Sales Down 1.4% in August: Crecon Report
October 10, 2012
- Companies Voice Concern over Implementation of Bar Code Labeling Due to Few Design Companies
October 9, 2012
- Zeria Terminates Development of Allergic Rhinitis Treatment
October 9, 2012
- Towa Consolidates Distribution Bases to 2 Sites in Eastern and Western Japan
October 9, 2012
- Takeda to Acquire LigoCyte of the US to Strengthen Vaccine Business
October 9, 2012
- Takeda Appeals to IP High Court in Actos Patent Lawsuit
October 9, 2012
- Ono, Carna Biosciences Conclude Capital Alliance Agreement, Making Ono Carna’s Largest Shareholder
October 9, 2012
- GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation
October 8, 2012
- All Sawai MRs to Use iPads, First for Generics Maker
October 5, 2012
- Data Acquisition Completed for Anti-HIV Treatment, Submission for Regulatory Approval in US, Europe Planned By Year End: Shionogi
October 5, 2012
- Novartis to See Tasigna Sales More than Double, Value of Glivec Maximized
October 5, 2012
- Kyowa Kirin Files for Approval Based on Public Knowledge for IM Administration and Dosage for Leunase
October 5, 2012
- Ono Conducts Nation’s First Microdosing Study for New Drug Candidate
October 5, 2012
- Bayer Files for Fosrenol for Patients with CKD in Preservation Period
October 5, 2012
- MTPC Outsources All Logistics Operations
October 5, 2012
- Takeda, Lundbeck File NDA for Major Depressive Disorder Treatment Vortioxetine in US
October 4, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…